Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

NCT: NCT03926520 · RECRUITING

NCT IDNCT03926520
StatusRECRUITING
Start Date2021-01-28
Completion2026-05-31

Brief Summary

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.

Frequently Asked Questions

What is Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)?

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) is a clinical trial registered under NCT03926520. Current status: RECRUITING.

What is the status of NCT03926520?

The current status of NCT03926520 (Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)) is: RECRUITING.

When did Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) start?

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD) started on 2021-01-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑